This content is machine translated Diabetic kidney disease Canagliflozin approved in fast track for diabetic nephropathy Kidney protection is extremely important for diabetes sufferers. Recently, canagliflozin became the first SGLT-2 inhibitor in Switzerland to receive a marketing authorization extension to reduce the risk of progression to…
View Post 4 min This content is machine translated AHA Scientific Sessions 2018 Dapagliflozin reduces heart failure hospitalization rate Diabetes is associated with an increased cardiovascular risk, which should be taken into account therapeutically. In 2015, the EMPA-REG OUTCOME study demonstrated positive cardiovascular effects of the SGLT-2 inhibitor empagliflozin.…
View Post 8 min This content is machine translated Insulin in type 2 diabetes When and in which combination? The current therapy guidelines for diabetes mellitus type 2 provide for the use of insulin as initial therapy as well as a later therapy option in monotherapy or in combination with…
